3OYW

Crystal structure of human galectin-1 in complex with thiodigalactoside


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.5 Å
  • R-Value Free: 0.245 
  • R-Value Work: 0.167 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model

Stannard, K.A.Collins, P.M.Ito, K.Sullivan, E.M.Scott, S.A.Gabutero, E.Darren Grice, I.Low, P.Nilsson, U.J.Leffler, H.Blanchard, H.Ralph, S.J.

(2010) CANCER LETT. --: --

  • DOI: 10.1016/j.canlet.2010.08.005
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • High level galectin-1 expression results in cancer cell evasion of the immune response, increased tumour survival and aggressive metastases. Using a galectin-1 polyclonal antibody, high levels of galectin-1 protein were shown to be expressed by breas ...

    High level galectin-1 expression results in cancer cell evasion of the immune response, increased tumour survival and aggressive metastases. Using a galectin-1 polyclonal antibody, high levels of galectin-1 protein were shown to be expressed by breast cancer cells established from FVB/N MMTV-c-neu mice as well as by the B16F10 melanoma cell line. In mixed lymphocyte cultures using tumour cells as antigenic stimulators, addition of recombinant galectin-1 dose-dependently inhibited lymphocyte production. Disaccharides were identified that inhibited galectin-1 function and increased growth and activation of CD8(+) CTL's killing cancer cells. X-ray crystallographic structures of human galectin-1 in complex with inhibitory disaccharides revealed their mode of binding. Combining galectin-blocking carbohydrates as adjuvants with vaccine immunotherapy in vivo to promote immune responses significantly decreased tumour progression and improved the outcomes for tumour challenged mice. This is the first report showing that suitably selected galectin-1 blocking disaccharides will act as adjuvants promoting vaccine stimulated immune responses against tumours in vivo.


    Organizational Affiliation

    School of Medical Science, Griffith University, Southport, QLD 4222, Australia. k.stannard@griffith.edu.au




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Galectin-1
A
134Homo sapiensMutation(s): 0 
Gene Names: LGALS1
Find proteins for P09382 (Homo sapiens)
Go to Gene View: LGALS1
Go to UniProtKB:  P09382
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Galectin-1
B
134Homo sapiensMutation(s): 0 
Gene Names: LGALS1
Find proteins for P09382 (Homo sapiens)
Go to Gene View: LGALS1
Go to UniProtKB:  P09382
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
TDG
Query on TDG

Download SDF File 
Download CCD File 
A, B
THIODIGALACTOSIDE
C12 H22 O10 S
SYKYBMOFPMXDRQ-ZFDCCPEWSA-N
 Ligand Interaction
Modified Residues  2 Unique
IDChainsTypeFormula2D DiagramParent
CSO
Query on CSO
A, B
L-PEPTIDE LINKINGC3 H7 N O3 SCYS
CME
Query on CME
A, B
L-PEPTIDE LINKINGC5 H11 N O3 S2CYS
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
TDGKd: 24000 - 78000 nM (100) BINDINGDB
TDGKd: 78000 nM BINDINGMOAD
TDGKd: 78000 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.5 Å
  • R-Value Free: 0.245 
  • R-Value Work: 0.167 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 44.368α = 90.00
b = 58.367β = 90.00
c = 111.793γ = 90.00
Software Package:
Software NamePurpose
PROTEUM PLUSdata collection
REFMACrefinement
SAINTdata reduction
SCALAdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2010-11-03
    Type: Initial release
  • Version 1.1: 2011-07-13
    Type: Version format compliance
  • Version 1.2: 2017-11-08
    Type: Refinement description